According to the law firm press release, Gentium S.p.A. is a biopharmaceutical company focused on the development and manufacturing of drugs to treat and prevent a variety of diseases and conditions, including vascular diseases related to cancer and cancer treatments.

On December 19, 2013, Gentium and Jazz jointly announced that they had entered into a tender offer agreement by which Jazz will acquire the Company for $57.00 per share in cash in a tender offer that will expire on January 22, 2014. The Complaint alleges that, in an attempt to secure shareholder support for the unfair Proposed Acquisition, on December 24, 2013, Gentium filed with the SEC a materially false and misleading Schedule 14D 9 Solicitation/Recommendation Statement (the “14D 9”), which was also disseminated to Gentium’s shareholders. The 14D 9, which recommends that Gentium’s shareholders tender their shares to Jazz, omits and/or misrepresents material information in contravention of §§14(e) and 20(a) of the 1934 Act regarding the unfair consideration offered in the Proposed Acquisition, and the actual intrinsic value of the Company.

On May 9, 2014, the Court appointed Lead Plaintiff and approved their selection of Lead Counsel. On September 2, 2014, the Lead Plaintiff filed an amended Complaint.

On January 22, 2015, the Court issued an Order granting Defendant's Motion to dismiss. The Clerk was directed to close this case.